Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karol E Watson

Showing results (11-20 of 180) with videos related to

Pageof 18
Sort By:
Reviews in Cardiovascular Medicine|January 17, 2007
Lowering levels of lipids and homocysteineKarol E Watson
Reviews in Cardiovascular Medicine|October 20, 2007
Novel therapies for cardiometabolic risk reduction and implications for clinical practiceKarol E Watson
Circulation. Cardiovascular Quality and Outcomes|March 10, 2016
Slippery Slope of Triglycerides: They Are Associated With Risk, But in the Statin Era, Does Targeting Them Confer Benefit?Karol E Watson, Philipp Wiesner
Trends in Cardiovascular Medicine|April 26, 2017
Triglycerides: A reappraisalPhilipp Wiesner, Karol E Watson
Women'S Health (London, England)|September 7, 2013
Predictors of cardiovascular risk in womenTamer Sallam, Karol E Watson
Trends in Cardiovascular Medicine|January 22, 2017
MY APPROACH to the Patient With Memory Loss Who Needs a StatinKarol E Watson, Tamer Sallam
Cardiovascular Research|November 8, 2021
Racial/ethnic health disparities in cardiovascular disease during the COVID-19 pandemic: revisiting a long-lasting problemCelso L Diaz, Karol E Watson
Reviews in Cardiovascular Medicine|September 13, 2018
Statin IntoleranceAlan S Brown, Karol E Watson
Reviews in Cardiovascular Medicine|August 11, 2004
Cardiovascular disease in African Americans. Closing the knowledge, treatment, and outcome gapKarol E Watson, Gregg C Fonarow
American Heart Journal|June 17, 2004
High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular eventsGregg C Fonarow, Karol E Watson
Pageof 18

Showing results (11-20 of 180) with videos related to

Sort By:
Pageof 18
Reviews in Cardiovascular Medicine|January 17, 2007
Lowering levels of lipids and homocysteineKarol E Watson
Reviews in Cardiovascular Medicine|October 20, 2007
Novel therapies for cardiometabolic risk reduction and implications for clinical practiceKarol E Watson
Circulation. Cardiovascular Quality and Outcomes|March 10, 2016
Slippery Slope of Triglycerides: They Are Associated With Risk, But in the Statin Era, Does Targeting Them Confer Benefit?Karol E Watson, Philipp Wiesner
Trends in Cardiovascular Medicine|April 26, 2017
Triglycerides: A reappraisalPhilipp Wiesner, Karol E Watson
Women'S Health (London, England)|September 7, 2013
Predictors of cardiovascular risk in womenTamer Sallam, Karol E Watson
Trends in Cardiovascular Medicine|January 22, 2017
MY APPROACH to the Patient With Memory Loss Who Needs a StatinKarol E Watson, Tamer Sallam
Cardiovascular Research|November 8, 2021
Racial/ethnic health disparities in cardiovascular disease during the COVID-19 pandemic: revisiting a long-lasting problemCelso L Diaz, Karol E Watson
Reviews in Cardiovascular Medicine|September 13, 2018
Statin IntoleranceAlan S Brown, Karol E Watson
Reviews in Cardiovascular Medicine|August 11, 2004
Cardiovascular disease in African Americans. Closing the knowledge, treatment, and outcome gapKarol E Watson, Gregg C Fonarow
American Heart Journal|June 17, 2004
High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular eventsGregg C Fonarow, Karol E Watson
Pageof 18